NCT03282916View on ClinicalTrials.gov

Anti-viral Therapy in Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions
Alzheimer DiseaseHerpes Simplex 1Herpes Simplex 2
Interventions
DRUG

Valacyclovir

Valacyclovir hydrochloride 500mg caplet

DRUG

Placebo

Placebo sugar pill 500mg caplet

Trial Locations (3)

10016

New York University School of Medicine, New York

10032

New York State Psychiatric Institute, New York

85006

Banner Alzheimer's Institute (BAI), Phoenix

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

Columbia University

OTHER

NCT03282916 - Anti-viral Therapy in Alzheimer's Disease | Biotech Hunter | Biotech Hunter